Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
- 1 February 1992
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 89 (3) , 972-976
- https://doi.org/10.1073/pnas.89.3.972
Abstract
In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or N epsilon-(2,3-diaminopropionyl)-D-lysine and N delta-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding affinities of peptides containing two cytotoxic side chains were lower. Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg5,D-Lys6,D-Ala10] LH-RH [where Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg5,N epsilon-(2,3-diaminopropionyl)-D-Lys6,D-Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3) is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr5,N epsilon-(2,3-diamino-propionyl)-D-Lys6,D-Ala10]LH-RH were linked to cytotoxic compounds. The hybrid molecules inhibited ovulation in rats at doses of 10 micrograms and suppressed LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited [3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and prostate cancers in vivo in animal models.Keywords
This publication has 21 references indexed in Scilit:
- Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studiesThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Membrane Receptors for Peptides in Experimental and Human Pancreatic CancersPancreas, 1989
- Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomataEuropean Journal of Cancer and Clinical Oncology, 1989
- Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancerJournal of Clinical Laboratory Analysis, 1989
- New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analoguesInternational Journal of Peptide and Protein Research, 1988
- Presence of somatomedin receptors on primary human breast and colon carcinomasCancer Letters, 1987
- Interaction between hypothalamic peptides in a superfused pituitary cell systemPeptides, 1984
- Receptor-mediated binding and uptake of GnRH agonist and antagonist by pituitary cellsPeptides, 1984
- 2-Methylanthraquinone derivatives as potential bioreductive alkylating agentsJournal of Medicinal Chemistry, 1980
- New analogs of luliberin which inhibit ovulation in the ratBiochemical and Biophysical Research Communications, 1979